Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patients

Annals of Hematology

Volumn 83, Issue 2, 2004, Pages 92-94

  Ziegler, Sophie ^a   Alt, E ^a   Brunner, M ^b   Speiser, W ^b   Minar, E ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b University School of Medicine   (Austria)

Author keywords

Acetyl salicylic acid; C reactive protein; Inflammation; Peripheral arterial occlusive disease; PFA 100; Platelet function analyzer system

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; THROMBO ASS;

ANALYZER; ARTICLE; CHI SQUARE TEST; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPOTHESIS; INFLAMMATION; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SYSTEMIC DISEASE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; MALE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS;

EID: 0742272032     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0789-8     Document Type: Article

References (23)

1. Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E et al (2000) Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 36:110-114
2. Fiotti N, Giansante C, Ponte E, Delbello C, Calabrese S, Zacchi T et al (1999) Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145:51-60
3. Li-Saw-Hee FL, Blann AD, Lip GJ (2000) Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic arterial fibrillation. Stroke 31:828-833
4. Isaka N, Tanigawa T, Nishikawa M, Nakano T (1998) High shear stress induced platelet aggregation (h-SIPA) and effects of antiplatelet therapy. Nippon Rinsho 56:2624-2629
5. Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, Jilma B (2000) Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 111:1250-1252
6. Gralnik HR, McKeown LP, Wilson OM, Williams SB, Elin RJ (1989) Von Willebrand factor release induced by endotoxin. J Laborat Clin Medicine 113:118-122
7. Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481-2485
8. Langlois M, Duprez D, Delanghe J, Buyzere M, Clement DL (2001) Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 103:1863-1868
9. Rossi E, Biasucci LM, Citterio F, Pellicioni S, Monaco C, Ginnetti F, et al (2002) Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 105:800-803
10. Ortel T, James AH, Thames EH, Moore KD, Greenberg CS (2000) Assessment of primary hemostasis by PFA-100 Analysis in a tertiatry care centre. Thromb Haemost 84:93-97
11. Von Pape KW, Aland E, Bohner J (2000) Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb Res 98:295-299
12. Albert MA, Ridker PM (1999) The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 1:99-104
13. McKenzie M, Gurbel PA, Levine DJ, Serebruany VL (1999) Clinical Utility of available methods for determining platelet function. Cardiology 92:240-247
14. Camici M (2002) C-reactive protein, atherosclerosis and cardiovascular disease. An update. Minerva Cardioangiol 50:327-331
15. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al (1997) Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26:517-538
16. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W (2000) Monitoring of asoirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83:316-321
17. Silva JA, White CJ (2002) Plaque instability in peripheral vessels. Prog Cardiovasc Dis 44:429-436
18. Van Genderen PJ, van Vliet HH, Prins FJ, van de Moesdijk D, van Strik R, Zijlstra FJ, Budde U, et al (1997) Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Hematol 75:215-220
19. Pernerstorfer T, Eichler HG, Stohlawetz P, Speiser W, Jilma B (2001) Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand Factor levels in healthy men. Atherosclerosis 155:389-393
20. Kaplan RC, Frishman WH (2001) Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. Heart Dis 3:326-332
21. Cheng TO (1999) Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. Clin Cardiol 22:A27
22. Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, et al (2002) Prevention of inflammation-induced endothelial dysfunction. A novel vasculo-protective action of aspirin. Circulation 105:2600-2604
23. Guarnieri G (1999) Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145:51-60